为解决大麻素临床应用受限问题，研究人员开展 CB1R 激动剂研究，发现新型激动剂可缓解疼痛且副作用少。 研究背景：大麻素药用的机遇与挑战 大麻素用于治疗疾病的历史可追溯至 15 世纪，然而在现代医学中，其作为镇痛药的应用却困难重重。大麻素具有多种 ...

The human body contains two primary cannabinoid receptors: CB1R and CB2R. CB1R is present in the human fetal cerebrum by the first weeks of the second trimester, and is the brain’s most abundant ...

The endocannabinoid system and its ability to regulate metabolism has held promise for the development of therapeutic agents to combat the growing epidemic of obesity. Two randomized, placebo ...